Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer
- PMID: 30393586
- PMCID: PMC6209422
- DOI: 10.1080/2162402X.2018.1474317
Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer
Abstract
Which subgroups patients with muscle-invasive bladder cancer (MIBC) could benefit most from adjuvant chemotherapy (ACT) is blurred. Here we tried to stratify MIBC patients with tumor infiltrating mast cells (TIMs), explore the prognostic and predictive value of TIMs, and provide possible cellular explanations. We selected 259 MIBC patients who underwent radical cystectomy from two independent clinical centers between 2002 and 2014. TIMs were evaluated and prognostic and predictive value was assessed. The CIBERSORT method, Gene Set Enrichment Analysis (GSEA) and differential gene expression analyses were performed to explore the possible cellular mechanisms. TIMs infiltration was distinct between stromal and epithelial area of MIBC specimens. Patients with higher stromal TIMs had a significant worse overall survival and recurrence free survival (HR = 2.228, 95%CI: 1.467-3.550; P = 0.001 and HR = 1.984, 95%CI: 1.105-3.374; P = 0.016). More importantly, pT2 patients with low stromal TIMs tended to have a lower risk of death and recurrence after ACT (HR = 0.233, 95%CI: 0.020-0.814; P = 0.033 and HR = 0.180, 95%CI: 0.022-0.722; P = 0.031). A negative correlativity between TIMs and CD8 + T cells was identified on TCGA-BLCA cohort. Immunohistochemistry results validated that high stromal TIMs were negatively correlated with CD8 + T cells (Spearman's rho = -0.215, P < 0.001). Differential gene expression suggested that low TIMs might represent a state of immune activation in MIBC. To conclude, high stromal TIMs infiltration was an independent unfavorable prognosticator for MIBC patients. Patients with low stromal TIMs might benefit the most from ACT, especially in pT2 stage.
Keywords: adjuvant chemotherapy; bladder cancer; mast cells; overall survival; prognosis; recurrence-free survival.
Figures




Similar articles
-
Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.Clin Cancer Res. 2018 Jul 1;24(13):3069-3078. doi: 10.1158/1078-0432.CCR-17-2687. Epub 2018 Mar 7. Clin Cancer Res. 2018. PMID: 29514839
-
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.BMC Cancer. 2018 Mar 21;18(1):313. doi: 10.1186/s12885-018-4220-1. BMC Cancer. 2018. PMID: 29562907 Free PMC article.
-
Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients.Ann Surg Oncol. 2022 Apr;29(4):2495-2503. doi: 10.1245/s10434-021-11155-y. Epub 2022 Jan 9. Ann Surg Oncol. 2022. PMID: 35000080
-
Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.Front Oncol. 2020 Oct 21;10:568279. doi: 10.3389/fonc.2020.568279. eCollection 2020. Front Oncol. 2020. PMID: 33194654 Free PMC article. Review.
-
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.Eur J Cancer. 2020 Jun;132:71-84. doi: 10.1016/j.ejca.2020.03.013. Epub 2020 Apr 22. Eur J Cancer. 2020. PMID: 32334338
Cited by
-
Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.Int J Med Sci. 2020 Mar 5;17(6):762-772. doi: 10.7150/ijms.42151. eCollection 2020. Int J Med Sci. 2020. PMID: 32218698 Free PMC article.
-
Identification of the Functions and Prognostic Values of RNA Binding Proteins in Bladder Cancer.Front Genet. 2021 Jun 22;12:574196. doi: 10.3389/fgene.2021.574196. eCollection 2021. Front Genet. 2021. PMID: 34239534 Free PMC article.
-
The role of human mast cells in allergy and asthma.Bioengineered. 2022 Mar;13(3):7049-7064. doi: 10.1080/21655979.2022.2044278. Bioengineered. 2022. PMID: 35266441 Free PMC article. Review.
-
Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture.J Immunother Cancer. 2020 Jun;8(1):e000651. doi: 10.1136/jitc-2020-000651. J Immunother Cancer. 2020. PMID: 32540859 Free PMC article.
-
A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.Eur J Med Res. 2023 Nov 15;28(1):515. doi: 10.1186/s40001-023-01496-7. Eur J Med Res. 2023. PMID: 37968767 Free PMC article.
References
-
- Advanced Bladder Cancer Meta-analysis C Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189–199; discussion 99–201. doi:10.1016/j.eururo.2005.04.005. - DOI - PubMed
-
- Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42–54. doi:10.1016/j.eururo.2013.08.033. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials